Pure Bioscience, INC 10-Q quarterly reports

PURE Bioscience reports increased net product sales for Q3 2026 compared to the prior year, though the company continues to operate at a net loss and faces going concern uncertainties.

PURE Bioscience, Inc. reported increased net product sales and reduced operating loss for the first fiscal quarter ended October 31, 2025, yet continues to face substantial doubt regarding its ability to continue as a going concern.

PURE Bioscience, Inc. filed its quarterly report, revealing ongoing net losses and a significant stockholders' deficiency, raising substantial doubt about its ability to continue as a going concern, despite increased revenue in the recent quarter and new convertible note financing from related parties.

PURE Bioscience reports a net loss of $1.487 million on net revenue of $947,000 for the six months ended January 31, 2025, raising substantial doubt about its ability to continue as a going concern.

PURE Bioscience reported a decrease in net product sales and a net loss for the first quarter of fiscal year 2025, while also raising additional capital through convertible notes.

PURE Bioscience reported increased revenue and gross margins for the third quarter of 2024, but continues to face challenges with ongoing losses and liquidity concerns.

PURE Bioscience saw a revenue increase in the second quarter of 2024, but ongoing losses and cash flow issues raise concerns about the company's ability to continue as a going concern.